Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15890546 | 0.93 | CYP2C9 (0.58) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL16900554 | 0.89 | HSD17B10 (0.54) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL8800403 | 0.83 | CTSB (0.62) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL10398153 | 0.83 | CYP2C9 (0.66) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL11634777 | 0.82 | HSD17B10 (0.59) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL922653 | 0.81 | ACHE (0.73) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL10163424 | 0.81 | ALOX15 (0.65) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL27786410 | 0.81 | CYP2A13 (0.67) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL2013061 | 0.81 | CYP2C9 (0.62) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 | |
| SCHEMBL31070282 | 0.81 | CYP2C9 (0.57) | CYP2C9HSD17B10ALOX15CTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113977-A1 | NON-POLYMERIC COUPLING AGENT FORMULATIONS FOR WOOD POLYMER COMPOSITES | ARKEMA INC. | 2023-04-13 | — | — | US | claimed |
| EP-4133007-A1 | NON-POLYMERIC COUPLING AGENT FORMULATIONS FOR WOOD POLYMER COMPOSITES | Arkema, Inc. (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115605534-A | Non-polymeric conjugate formulations for wood polymer composites | 阿科玛股份有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| EP-3755675-B1 | ACCELERATED PEROXIDE-CURED RESIN COMPOSITIONS HAVING EXTENDED OPEN TIMES | ARKEMA INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12486381-B2 | Accelerated peroxide-cured resin compositions having extended open times | ARKEMA INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-3559153-B1 | EFFICIENT CURATIVE FOR FREE RADICALLY-CROSSLINKABLE POLYMERS | ARKEMA INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129240-A1 | METHOD FOR CURING A CURABLE COMPOSITION | ARKEMA FRANCE (FR) | 2025-04-24 | — | — | US | disclosed |
| US-20250115738-A1 | PEROXIDE FORMULATIONS WITH ANTI-SCORCH PROPERTIES | ARKEMA FRANCE (FR) | 2025-04-10 | — | — | US | disclosed |
| CN-119522253-A | Peroxide formulations with scorch resistant properties | 阿科玛法国公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3230350-B1 | COMPOSITIONS AND METHODS FOR CROSSLINKING POLYMERS IN THE PRESENCE OF ATMOSPHERIC OXYGEN | ARKEMA INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| EP-1212296-B9 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1212296-B1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6596772-B1 | Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are | SUGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-4314011-A | DISCOLORATION INHIBITORS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1982-02-02 | — | — | US | disclosed |
| US-4254216-A | ANTIFADING ADDITIVE FOR FILMS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138255-A1 | Phosphate mimics and methods of treatment using phosphatease inhibitors | PPP4C, PTPRO, PTPRS | CYP2C9 3881/4885HSD17B10 4100/4885ALOX15 4658/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | CYP2C9 4879/4885HSD17B10 3689/4885ALOX15 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.